Secondary infections are a major complication of sepsis and associated with a compromised immune state, called sepsis-induced immunoparalysis. Molecular mechanisms causing immunoparalysis remain unclear; however, changes in cellular metabolism of leukocytes have been linked to immunoparalysis. We investigated the relation of metabolic changes to antimicrobial monocyte functions in endotoxin-induced immunotolerance, as a model for sepsis-induced immunoparalysis. In this study, immunotolerance was induced in healthy males by intravenous endotoxin (2 ng/kg, derived from Escherichia coli O:113) administration. Before and after induction of immunotolerance, circulating CD14 + monocytes were isolated and assessed for antimicrobial functions, including cytokine production, oxidative burst, and microbial (Candida albicans) killing capacity, as well metabolic responses to ex vivo stimulation. Next, the effects of altered cellular metabolism on monocyte functions were validated in vitro. Ex vivo lipopolysaccharide stimulation induced an extensive rewiring of metabolism in naive monocytes. In contrast, endotoxin-induced immunotolerant monocytes showed no metabolic plasticity, as they were unable to adapt their metabolism or mount cytokine and oxidative responses. Validation experiments showed that modulation of metabolic pathways, affected by immunotolerance, influenced monocyte cytokine production, oxidative burst, and microbial (C. albicans) killing in naive monocytes. Collectively, these data demonstrate that immunotolerant monocytes are characterized by a loss of metabolic plasticity and these metabolic defects impact antimicrobial monocyte immune functions. Further, these findings support that the changed cellular metabolism of immunotolerant monocytes might reveal novel therapeutic targets to reverse sepsis-induced immunoparalysis.
INTRODUCTION
Secondary infections represent a major complication for patients admitted to the intensive care unit (ICU) with sepsis. 1 In sepsis, hyperinflammatory responses to infection are accompanied and/or followed by counterregulatory anti-inflammatory responses, which can cause a dysfunctional state in which immune cells are unable to adequately respond to pathogens. 2 This phenomenon, called sepsis-induced immunoparalysis, is associated with increased susceptibility to secondary (opportunistic) infections. 3 Microbial infections in the late phase of sepsis including bacteria (e.g., Escherichia coli
and Staphylococcus aureus), fungi (e.g., Candida albicans), and viral reactivation all illustrate the clinical significance of sepsis-induced immunoparalysis, which is associated with increased ICU length of stay. [4] [5] [6] Moreover, the dysregulated host response is considered to be a critical factor that contributes to the persistently high mortality in sepsis, as a result of secondary infections. 7, 8 Monocytes are severely affected during immunoparalysis, and they play a pivotal role in the host response during sepsis. A low human leukocyte antigen-antigen D related (HLA-DR) expression on monocytes coincides with an increase in nosocomial infections and higher mortality. 9, 10 Another hallmark of sepsis-induced immunoparalysis are impaired ex vivo monocyte cytokine responses, which are likely a result of cellular reprogramming. 11 Therefore, reversing or preventing monocyte immunotolerance represents an attractive strategy to improve immune function and outcome of sepsis. 12 To facilitate the development of effective therapies, the molecular mechanisms underlying the immunotolerant state of monocytes should be unraveled.
In the past decade, it has become clear that during sepsis immune function and cellular metabolism are closely interlinked. 13 A previous study revealed dysfunction of cellular metabolism in immunotolerant monocytes. 14 Recently, in vitro LPS tolerization was found to induce prominent metabolic changes over time in THP-1 monocyte cells. 15 This study demonstrated a consecutive metabolic adaptation of these cells during immune activation, deactivation (tolerance), and resolution of inflammation. These findings support the notion that metabolic rewiring after immune stimulation may be a major mechanism that drives the tolerant state of immune cells. Importantly, this study highlights the need for in vivo studies to further characterize metabolic changes in tolerant immune cells and the impact on immune function in parallel with this metabolic shift. A clear understanding of the essential metabolic routes affected during immunoparalysis and how they interfere with immune function is still lacking. This knowledge gap needs to be bridged before effective therapies can be developed.
In the current study, the primary aim was to better understand the potentially defective adaptation of monocyte metabolic responses during immunoparalysis. To this end, a standardized protocol 16 of endotoxin-induced immunotolerance was employed, where human subjects were intravenously challenged with endotoxin (E. coli LPS)
to model sepsis-induced immunoparalysis. Monocytes were studied before, during, and 1 week after endotoxin-induced immunotolerance to characterize metabolic changes associated with immunotolerance and long-lasting metabolic reprogramming following endotoxin challenge. First, the metabolic profile and immunological functions were characterized ex vivo before immunotolerance, during immunotolerance and 1 week after immunotolerance. Second, metabolic pathways found to be affected were validated for their impact on antimicrobial functions in naive monocytes.
MATERIALS AND METHODS

Experimental human endotoxemia model
Experimental human endotoxemia was used as a model for sepsisinduced immunoparalysis, as extensively described in previously published studies. 16, 17 After written informed consent was obtained, blood samples from healthy male volunteers were collected. Subjects participated in two similarly designed endotoxemia studies (NL54870. supplemented with pyruvate (1 mM; Gibco), glutamax (2 mM; Gibco), and gentamicin (50 g/ml; Centrafarm, Etten-Leur, the Netherlands).
Classical monocytes were subsequently isolated from the PBMC fraction using magnetic beads labeled with anti-CD14 (protocol: MACS Miltenyi, Bergisch Gladbach, Germany). Finally, cells were counted using the Sysmex XN-450 automated differential hematology analyzer (Sysmex Corporation, Kobe, Japan).
Ex vivo experiments
Isolated CD14+ monocytes were plated in 96-well tissue treated flatbottom plates (1.0 × 10 5 cells/well; Eppendorf, Hamburg, Germany) and stimulated with RPMI or E. coli LPS (10 ng/ml; serotype 055:B5, Sigma-Aldrich) for 24 h at 37 • C and 5% CO 2 . Monocyte cytokine responses were measured in supernatants of 15 endotoxin-challenged subjects and 6 placebo subjects.
Monocyte metabolic profiling
Metabolic profiling was performed on ex vivo LPS-restimulated and unstimulated CD14+ monocytes isolated from 5 randomly selected volunteers that were infused with endotoxin. Samples were placed in sterile micro centrifuge tubes (2 × 10 6 cells/tube in a volume of 1 ml). Cell pellets were snap frozen in liquid nitrogen and shipped to 
Ex vivo monocyte oxidative capacity
In the NL61136.091.16 endotoxemia cohort, oxidative burst capacity was determined in isolated CD14+ of 10 male volunteers (n = 6 endotoxemia challenged, n = 4 placebo). For these experiments, the total production of reactive oxygen species (ROS) generated by monocytes was measured in flat-bottomed white tissueculture treated 96 well plates (Sigma-Aldrich, Saint Louis, MO, USA)
To every well, 20 l of 3-aminophthalhydrazide, 5-amino-2,3-dihydro- The percentage of killed microbes was calculated as 1 − (CFU remained after incubation with microbes/CFU determined before incubation with microbes) × 100. 
In vitro model for modulation of metabolic pathways
PBMC stimulation experiments
After 24 h preincubation with modulators, PBMCs (5.0 × 10 5 cells/well)
were stimulated with heat-inactivated E. coli (1.0 × 10 7 bacteria/ml, clinical isolate ATCC35218), S. aureus (1.0 × 10 7 /ml, clinical isolate ATCC25923), and C. albicans (1.0 × 10 6 /ml, strain UC820) for 24 h.
Cytokines were measured in supernatants to assess the effects of metabolic modulation on cytokine responses.
In vitro oxidative burst assays
Similarly, the effects of metabolic modulation on oxidative burst were determined. Supernatants of seeded PBMCs (5.0 × 10 5 cells/well) 
In vitro NADPH assays
For the detection of intracellular NADPH, isolated PBMCs were plated in 12-wells flat round-bottom plates with a density of 4.5 × 10 6 cells/well. PBMCs were preincubated for 24 h with various modulators, as described before (Table 1) . After stimulation for 24 h, stimuli and metabolic modulators were washed away and the intracellular nucleotide NADPH was measured, using Colorimetric 
In vitro microbial killing assays
After removal of the metabolic modulators, PBMCs were washed twice with warm PBS in order to prevent interference of the metabolic inhibitors and stimuli with the live C. albicans. PBMCs were stimulated with RPMI, or C. albicans (2 × 10 5 yeast/well, UC820) for 24 h at 37 • C and 5% CO 2 . After incubation, all cells were lysed in water, and serial dilutions of lysates were plated on Sabouraud agar plates (Becton Dickinson, Heidelberg, Germany). The Candida killing capacity of the PBMCs was quantified by counting remaining CFUs overnight incubation at 37 • C and 5% CO 2 . The killing capacity was calculated as described before.
In vitro viability assays
To determine the effect of the inhibitors and stimuli of specific metabolic pathways on cell viability in PBMCs, apoptosis was assessed using Annexin-V and propidium iodide (PI) staining. Cells were stained for 15 min in 300 l RPMI containing 1 l Annexin-V (Biovision) and 5 mM CaCl 2 . Immediately before measurement 1.5 l PI (Invitrogen Molecular Probes) was added. Cells were measured using a CytoFLEX cytometer (Beckman Coulter).
Cytokine measurements
Cytokine measurements of all experiments were performed in col- 
Statistical analysis
The data are represented as the mean ± SEM or median, based on their distribution. One-way ANOVA for repeated measurements was used to compare statistical differences for the means of the respective time points. Dunn's multiple comparison test was used as a post hoc test. The Wilcoxon signed rank test was performed to compare means for significant differences of metabolic modulation in validation experiments. Calculations and statistical analysis were performed with GraphPad Prism Version 5.03 (San Diego, CA, USA.) All computational analyses for metabolome data analysis were performed in the R programming language. 20 For metabolomics, a pathway analysis was assessed. Each metabolite was assigned to a pathway by Metabolon, and enrichments were calculated for these pathways, comparing two conditions at a time. The conditions that were compared are 4 h (4h) versus baseline, 7 days (7d) versus 4 h (4h), and 7 days (7d) versus baseline. The R package "gage" was used to calculate pathway enrichment, which used log2 metabolite concentrations as an input. 21 All calculations were performed in a paired fashion, F I G U R E 1 Endotoxin-induced monocyte tolerance affects monocyte effector functions. (A) Kinetics of ex vivo LPS-induced IL-1 , TNF-, IL-6, IL-10, and IL-1Ra levels in culture supernatants of CD14+ monocytes that were isolated from healthy volunteers at baseline (BL), 4 h (4h), and 7 days (7d) after administration of endotoxin (2 ng/kg, red lines, n = 15) or placebo (0.9% saline, black lines, n = 6). Data are presented as (mean ± SEM) percentage change compared to baseline measurements. Differences within groups over time were analyzed using the Friedmann test with Dunn's post hoc test for multiple comparisons. **P < 0.01, ***P < 0.001. (B) Kinetics of ex vivo E. coli, S. aureus, or C. albicans induced ROS production (AUC relative light units) in isolated CD14+ monocytes from healthy volunteers for all time points. Red lines present subjects challenged with endotoxin (n = 6); black lines show placebo controls (n = 4). Data are presented as mean ± SEM. Means were compared for significance using the Friedmann test with Dunn's post hoc test to illustrate differences between defined time points. *= P < 0.05. (C) Ex vivo intracellular killing of C. albicans phagocytized by CD14+ monocytes isolated at baseline (BL), 4 h (4h) and 7 days (7d) in (n = 5) endotoxin-challenged subjects, presented for each subject separately. The killing was calculated for duplicates and serial dilutions as 1 -(CFU remained after incubation with microbes/CFU determined before incubation with microbes) × 100%, hence presented as the percentage of Candida killing. Data are shown as the mean ± SEM. BL versus 4 h was statistically compared for each subject (*= P < 0.05, **= P < 0.01) with the Mann-Whitney U test
and P-values were calculated using a 2-sided paired t-test. A BenjaminiHochberg false discovery rate procedure was used to correct these P-values for type I errors. 22 Different sample normalization methods were attempted, including total area normalization, and techniques more robust to outliers like the normalization method available in the DESeq2 package. 23 In the end, it was found that normalization was not required, since the same amount of sample was used for each measurement, and the values should be semiquantitative. A P-value < 0.05 was considered statistically significant with *P < 0.05, **P < 0.01, and ***P < 0.001.
RESULTS
Endotoxin-induced immunotolerance affects monocyte cytokine responses, microbial killing capacity, and oxidative burst
Intravenous endotoxin administration induces immunotolerance in circulating monocytes in healthy volunteers, and these otherwise highly responsive cells are rendered irresponsive to ex vivo re-challenge with LPS. 16 ,18,19 Accordingly, we confirmed that monocytes isolated 4 h after in vivo endotoxin administration were irresponsive to ex vivo LPS stimulation (Fig. 1A) . This effect was restored 7 days following endotoxemia. In contrast, monocyte cytokine responses to ex vivo LPS stimulation were unaffected in placebo subjects.
After in vivo endotoxin-induced immunotolerance, monocytes showed a significant attenuated capacity to induce an oxidative burst response to E. coli and S. aureus (Fig. 1B) . A similar trend toward C. albicans-induced ROS release was observed. Finally, the microbial killing was investigated during endotoxin-induced immunotolerance. After in vivo endotoxin challenge, monocytes showed a reduced Candida killing capacity in 2/5 subjects (Fig. 1C) . The effect of endotoxin tolerance on microbial killing in the other volunteers was inconclusive, with one volunteer showing even enhanced monocytemediated Candida killing during tolerance.
Endotoxin-induced immunotolerance reduces the metabolic plasticity of monocytes
Monocytes isolated from 5 volunteers that were infused with endotoxin were ex vivo LPS-restimulated or left unstimulated for 24 h.
Metabolic profiling of the monocytes was performed after stimulation at baseline, 4 h postendotoxin infusion, and 7 days postendotoxin Fig. 2A and Table S1 ). In contrast, in immunotolerant monocytes obtained 4 h following in vivo endotoxemia, almost the full metabolic profile was down-regulated compared to baseline in untreated monocytes (Fig. S1A, left panel) . Also ex vivo LPS stimulation did not significantly upregulate abundance of metabolites; except for quinolinate, a downstream product of the kynurenine pathway, which was significantly increased (Fig. 2A , Table S1 , and Fig. S1 ). Monocytes isolated 7 days following in vivo endotoxin administration showed only a partially recovered metabolic response upon ex vivo LPS stimulation. A total of 26 metabolites were significantly upregulated, of which 13 overlapped with the metabolic response at baseline (Fig. 2B and Table S1 ) (Fig. 2D) . Furthermore, numerous pathways were downregulated, especially those involved in lipid metabolism such as biosynthesis of membrane-bound lipids (phospholipids, sphingolipids, and glycerol-based phospholipids) and fatty acid regulation (Fig. 2D) . In contrast, endotoxin-induced immunotolerance did not display modulation of these metabolic pathways after ex vivo LPS stimulation. Instead, the synthesis of dipeptides was highly induced (Fig. 2D ). Metabolic plasticity of ex vivo LPS-stimulated monocytes was only partially restored 7 days following in vivo endotoxemia with still key metabolic pathways dysregulated such as glycolysis, TCA cycle, methionine, cysteine, S-adenosyl-methionine and taurine metabolism, phospholipid metabolism, and sphingolipid metabolism. At this time point, ex vivo LPS stimulation induced down-regulation of the fatty acid metabolism (acylcarnitine), whereas this pathway was not significantly affected at other time points (Fig. 2D) , which highlights the changed metabolic response 7 days after endotoxin infusion.
Modulation of cellular metabolism in naive immune cells differentially influences cytokine responses
The metabolic profiling of monocytes indicated a significant loss of metabolic plasticity in immunotolerant monocytes. Therefore, the influence of cellular metabolism on immune functions including cytokine production, oxidative burst, microbial (Candida) killing, and cell viability were determined. Metabolic pathways affected by immunotolerance were systematically targeted by inhibitors/ modulators at crucial steps in the metabolic pathways ( Fig. 3A and Table 1 ). The effect of each metabolic modulation on cell viability was measured after 24 h and did not reveal reduced cell viability compared to their respective vehicle control (Fig. S2) (Fig. 3B-D) . None of the metabolic inhibitions reduced E.
coli-induced cytokine responses as expected, but instead increased cytokine responses were observed (Fig. 3B) . Inhibition of glutaminolysis with bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES) significantly reduced TNF-concentrations in response to S. aureus and C. albicans ( Fig. 3C and D) . Inhibition of the PPP with 6-aminonicotinamide (6AN) significantly reduced C. albicans-induced IL-6 production. Inhibition of glycolysis with 2-deoxy-D-glucose (2DG)
showed a trend in reduced C. albicans-induced TNF-and IL-1 production (Fig. 3D) , but increased E. coli-induced cytokine responses.
Notable, cytokine responses were consistently induced for all three microbial stimuli after stimulation of the TCA cycle with potassium dichloroacetate (DCA) (Fig. 3B-D) .
Glycolysis, PPP, and glutaminolysis are crucial for oxidative burst
The oxidative burst of in vitro LPS-tolerized PBMCs was assessed to confirm that immunotolerance corresponds with reduced oxidative responses. Indeed reduced ROS release upon microbial restimulation was observed in LPS-tolerized PBMCs ( Inhibition of pathways known to fuel NADPH (glycolysis, PPP, and glutaminolysis) reduced ROS release, while modulation of pathways leading to increased NADPH levels (DCA and NAC) increased ROS release (Fig. 4C) . Measurements of intracellular NADPH levels following modulation of these NADPH-dependent pathways validated this.
The blockade of glycolysis using 2DG reduced intracellular NADPH levels if pyruvate was absent in the media, whereas NAC and DCA increased intracellular NADPH levels (Fig. 4D) . No changes in intracellular NADPH concentrations were detected by the inhibition of PPP or glutaminolysis.
Immunotolerance is associated with reduced Candida killing capacity
In vitro experiments showed a significantly reduced killing capacity for C. albicans in LPS-induced tolerant monocytes (Fig. 5A) . Inhibition of glycolysis (2DG) did consistently reduce Candida killing capacity in n = 10), C75 (fatty acid metabolism, n = 9), ETO (fatty acid metabolism, n = 15), NAC (glutathione synthesis, n = 14), BSO (glutathione synthesis, n = 12), BPTES (glutaminolysis, n = 19), and C968 (glutaminolysis, n = 7). Data are shown as the median with P-value of statistical comparison by the Wilcoxon Signed Rank Test (*P < 0.05, **P < 0.01, and ***P < 0.001). (C) Simplified schematic overview of the metabolic pathways that were targeted with inhibitor (green labels) or stimulator (red labels) that could lead to increased intracellular NAPDH levels (green arrows) or decreased (red dotted line) NADPH levels. (D) Relative changes in monocyte intracellular NADPH levels measured by colorimetric assay following treatment of the cells for 24 h with various modulators of cellular metabolism (n = 6, red bars). Fold changes are relative to the appropriate vehicle control (black bars; either RPMI, or RPMI without pyruvate [-PYR], or DMSO). Bars represent the mean ± SEM and were compared for significance using the Wilcoxon Signed Rank Test (*P < 0.05) healthy donors, but only when pyruvate was excluded from the culture media during the preincubation period (Fig. 5B) . Modulation of the TCA cycle and PPP did influence Candida killing but showed high variability between donors. We found that inhibition of glutaminolysis (BPTES or C968) exhibited a substantial impact on Candida killing in naive monocytes (Fig. 5C ). Glutathione precursor NAC augmented killing capacity in the majority of the donors, whereas other donors showed unchanged killing capacity. In some donors, killing capacity was even reduced upon NAC treatment. Remarkably, experiments with reduced or increased glutamine levels in culture media demonstrated similar trends.
Reduced oxidative burst in monocytes correlates with defective microbial killing mechanisms
Our data demonstrate that central metabolic pathways like glutaminolysis and glycolysis are both involved in ROS generation (Fig. 4B) and candida killing in naïve monocytes ( Fig. 5B and C) . The importance of ROS production for host defense is demonstrated in patients, with genetic defects in the NADPH oxidase complex, who are unable to produce ROS and are highly susceptible to staphylococcal and Aspergillus infections. 24 Hypothetically, metabolic modulation might have influenced monocyte antimicrobial functions in similar ways; by altering NADPH-dependent oxidative burst, thereby influencing phagocytic activity and killing capacity (Fig. 6A ). To test this hypothesis, we investigated the correlation between C. albicans-induced oxidative burst and fungal killing (Fig. 6B ). In these experiments, C. albicans killing was measured in the presence of diphenyleneiodonium (DPI). DPI is a frequently used and potent ROS inhibitor mediated by flavoenzymes, in particular NADPH oxidase. 25 As expected, DPI-treated monocytes demonstrated drastically reduced capacity to mount an oxidative burst (Fig. 6C) . In parallel, we observed a reduced capacity of monocytes to kill C. albicans yeasts, confirming the link between ROS and killing ( Fig. 6D ).
F I G U R E 5 Intracellular microbial killing in vitro. (A)
In vitro microbial killing capacity by PBMCs after incubation with C. albicans (n = 8) with 24 h pre-exposure (red bars) to LPS compared to media control without LPS (black bars). (B,C) In vitro C. albicans killing in PBMCs after 24 h preexposure to modulators (red bars) of (B) glycolysis (2DG, n = 16, 2DG-PYR, n = 7) TCA cycle (DCA, n = 14), PPP (6AN, n = 12), (C) glutaminolysis (BPTES, n = 16 or C968, n = 6), glutathione synthesis (NAC, n = 19), or glutamine metabolism (-glutamine, n = 11, 2xglutamine, n = 8) compared to the unmodulated situation. All data in this figure are presented as the mean ± SEM and with a significant P-value of statistical comparison by the Wilcoxon signed rank test (*P < 0.05, **P < 0.01) In line with these findings, we showed a homogeneous metabolic response of naïve monocytes to ex vivo LPS stimulation. Similarly, we observed significant differences in metabolic adaptation between unstimulated and LPS-stimulated monocytes in the progression of activation to tolerant and resolution of the inflammatory state. In contrast to TPH-1 cells, 15 we observed heterogeneity in the metabolic responsiveness during immunotolerance in healthy subjects. This suggests that metabolic remodeling is individual-specific. These changes may In an attempt to translate pathophysiological mechanisms into clinical practice, we used an in vivo endotoxemia model to simulate the biphasic response of sepsis. This model is widely used to study the early and transient phase of sepsis, illustrated by a controlled systemic inflammatory response in healthy subjects. 26 Systemic endotoxin-induced responses in this model are milder than that suffered by septic patients, who by definition suffer from organ injury. This is reflected by the fact that endotoxin-challenged volunteers recover fully without residual deficits and can be discharged 8 h after challenge. 16, 18, 19 In contrast, sepsis-associated organ dysfunction is often life-threatening and assessed in all patients suspected of sepsis. 27 Moreover, severe sepsis survivors have an increased risk of long-term deficits including physical and cognitive impairment. 28 Given that, in experimental endotoxemia, already major (long-lasting) defects in metabolic plasticity of monocytes were observed, we envision that during sepsis the severe impact on the immune system may trigger even more severe changes in cellular metabolism. This possibly contributes to the sustained immune dysfunction in septic patients, who develop secondary infections days to weeks after diagnosis. 7, 29 Of note, systemic LPS stimulation can result in opposite immune responses in vivo. 30 Several studies showed that LPS priming with low concentrations could augment immune responses, resembling in a proinflammatory phenotype. [30] [31] [32] However, in line with other endotoxemia studies, we showed a proper immunotolerant phenotype in the current study. 16, 18, 19 Essential metabolic differences were found between homeostasis and endotoxin-induced immunotolerance, which may reveal biomarkers or therapeutic targets for immunoparalysis. The untargeted metabolome analysis identified the metabolites quinolinate and kynurenine to be upregulated, respectively 4 h and 7 days after endotoxin administration. These are metabolites of the tryptophankynurenine pathway, which is known to be activated or dysregulated in several inflammatory conditions including infectious diseases, autoimmune disorders, malignancy, and cardiovascular diseases. 33 Accumulation of kynurenine and downstream metabolites, through increased tryptophan degradation by IDO-1, contributes to hypotension due to vasodilatation, and is therefore considered as a novel target for septic shock treatment. 34 Besides these vascular effects, alterations in this pathway correlate with disease severity and impaired immune function. 35 Although kynurenines might be linked to and showed diverse cellular reprogramming depending on the stimulus, experimental setup, and cell population. 14, [36] [37] [38] [39] Glycolysis is essential for host defense against C. albicans infection. 40 Glycolysis inhibition decreased cytokine response to C. albicans stimulation, but increased upon E. coli or S. aureus stimulation in our experiments.
These divergent cytokine responses may be the result of differences in pathogen recognition receptor-mediated signaling pathways, as well as metabolic changes, induced upon stimulation with crucially different microbes. 39 Oxidative responses are classically linked to the early hyperinflammatory phase of sepsis and associate with increased organ damage. 41 However, during monocyte immunotolerance, impaired ROS production was observed, 42 and attenuated superoxide production was reported after ex vivo restimulation of monocytes from septic patients. 43 In line with this, we observed impaired oxidative burst in immunotolerant monocytes, both ex vivo and in vitro. The metabolic routes involved in ROS production are glycolysis, PPP, glutaminolysis, TCA cycle, and glutathione synthesis. Modulation of NADPH-yielding pathways, including glycolysis, glutathione metabolism, or the TCA cycle influenced intracellular NADPH levels in our experiments significantly. However, the PPP and glutaminolysis are considered essential sources of NADPH generation for cells 44-46 ; controversially, these were not significantly altered in our experiments upon inhibition.
Oxidative burst is crucial for antimicrobial defense. 24 In line with this, we observed a correlation between killing capacity and oxidative Glutamine has gained clinical interest as it has regulatory effects on immune cell function and may serve as a beneficial supplement in critically ill patients. 47 We observed variation in monocyte killing capacity in glutamine poor or supplemented conditions.
In line with this, trials in critically ill patients similarly observed divergent outcomes upon glutamine supplementation. 48, 49 Some studies demonstrated benefits in critically ill patients, including decreased mortality and infection risk, [50] [51] [52] but it is now debated that glutamine supplementation can further elucidate hyperinflammation. 53 The benefit of modulating glutamine metabolism, therefore, may depend on the individual inflammatory state. Second, DCA was used in a clinical trial to treat hyperlactatemia, which included patients with septic shock, but did not improve clinical outcome. 56 Besides reducing lactate levels, DCA activates the pyruvate dehydrogenase complex (PDC) and stimulates mitochondrial glucose oxidation through increased mitochondrial pyruvate influx. 57 DCA in a sepsis mouse model promoted restoration of immunometabolism, increased survival, and improved bacterial clearance. 58 New insights and the data presented here suggest that the modulators DCA and NAC might be reconsiderable targets in sepsis treatment. However, the aforementioned trials with DCA and NAC focused on the hyperinflammatory aspects of sepsis.
One can speculate that timing of treatment and the heterogeneity of populations enrolled in these trials have concealed beneficial effects in patients subgroups, in particular for patients with profound
immunosuppression. This provides a rationale for future studies on the use of these metabolic modulators in patients with sepsisinduced immunoparalysis.
Our study has some limitations. First, metabolomic profiling was performed in a small number of participants. Therefore, validation experiments were focused on metabolic pathways rather than on single metabolites. We assume that parallel to pathway analyses, individual metabolites may help to identify novel metabolic therapeutic targets. Second, our study population was within an age range of 18-35, whereas 64.9% of cases of sepsis occurs in patients at or over the age of 65. 59 Immune metabolism is a research field that is relatively new, and knowledge on the differences in immunometabolic reprogramming between adults and the elderly is scarce. Our results may, therefore, not be generalizable to populations that commonly develop sepsis. Third, our sepsis model focused on the activation of the innate immune system, although sepsis-induced immunoparalysis is characterized by defects in both innate and adaptive immunity. 
